A $3.15bn deal follows a December 2024 option agreement.
ApexOnco Front Page
Recent articles
The groups spend big on Terns and Arcellx.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The restructured biotech’s new lead project enters phase 1.
The company will imminently start its third pivotal trial of PF-08634404.
The company ditches lorigerlimab in prostate cancer.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
